<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>45</viewCount><searchCount>0</searchCount></scores><additional><omics_type>Unknown</omics_type><volume>48(12)</volume><submitter>Ruschoff JH</submitter><funding>Universität Zürich</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. We investigated histopathological parameters and immunohistochemical PSMA expression patterns on radical prostatectomy (RPE) specimens and correlated them to the corresponding &lt;sup>68&lt;/sup>Ga-PSMA-11-PET examinations.&lt;h4>Methods&lt;/h4>RPE specimens of 62 patients with preoperative &lt;sup>68&lt;/sup>Ga-PSMA-11-PET between 2016 and 2018 were analysed. WHO/ISUP grade groups, growth pattern (expansive vs. infiltrative), tumour area and diameter as well as immunohistochemical PSMA heterogeneity, intensity and negative tumour area (PSMA&lt;sub>%neg&lt;/sub>) were correlated with spatially corresponding SUV&lt;sub>max&lt;/sub> on &lt;sup>68&lt;/sup>Ga-PSMA-11-PET in a multidisciplinary analysis.&lt;h4>Results&lt;/h4>All tumours showed medium to strong membranous (2-3 +) and weak to strong cytoplasmic (1-3 +) PSMA expression. Heterogeneously expressed PSMA was found in 38 cases (61%). Twenty-five cases (40%) showed at least 5% and up to 80% PSMA&lt;sub>%neg&lt;/sub>. PSMA&lt;sub>%neg&lt;/sub>, infiltrative growth pattern, smaller tumour area and diameter and WHO/ISUP grade group 2 significantly correlated with lower SUV&lt;sub>max&lt;/sub> values. A ROC curve analysis revealed 20% PSMA&lt;sub>%neg&lt;/sub> as an optimal cutoff with the highest sensitivity and specificity (89% and 86%, AUC 0.923) for a negative PSMA-PET scan. A multiple logistic regression model revealed tumoural PSMA&lt;sub>%neg&lt;/sub> (p &lt; 0.01, OR = 9.629) and growth pattern (p = 0.0497, OR = 306.537) as significant predictors for a negative PSMA-PET scan.&lt;h4>Conclusions&lt;/h4>We describe PSMA&lt;sub>%neg&lt;/sub>, infiltrative growth pattern, smaller tumour size and WHO/ISUP grade group 2 as parameters associated with a lower &lt;sup>68&lt;/sup>Ga-PSMA-11 uptake in prostate cancer. These findings can serve as fundament for future biopsy-based biomarker development to enable an individualized, tumour-adapted imaging approach.</pubmed_abstract><journal>European journal of nuclear medicine and molecular imaging</journal><pagination>4042-4053</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8484204</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>What's behind &lt;sup>68&lt;/sup>Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.</pubmed_title><pmcid>PMC8484204</pmcid><pubmed_authors>Moch H</pubmed_authors><pubmed_authors>Hermanns T</pubmed_authors><pubmed_authors>Ruschoff JH</pubmed_authors><pubmed_authors>Burger IA</pubmed_authors><pubmed_authors>Rupp NJ</pubmed_authors><pubmed_authors>Muehlematter UJ</pubmed_authors><pubmed_authors>Rodewald AK</pubmed_authors><pubmed_authors>Eberli D</pubmed_authors><pubmed_authors>Ferraro DA</pubmed_authors><pubmed_authors>Laudicella R</pubmed_authors><view_count>45</view_count></additional><is_claimable>false</is_claimable><name>What's behind &lt;sup>68&lt;/sup>Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.</name><description>&lt;h4>Purpose&lt;/h4>Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. We investigated histopathological parameters and immunohistochemical PSMA expression patterns on radical prostatectomy (RPE) specimens and correlated them to the corresponding &lt;sup>68&lt;/sup>Ga-PSMA-11-PET examinations.&lt;h4>Methods&lt;/h4>RPE specimens of 62 patients with preoperative &lt;sup>68&lt;/sup>Ga-PSMA-11-PET between 2016 and 2018 were analysed. WHO/ISUP grade groups, growth pattern (expansive vs. infiltrative), tumour area and diameter as well as immunohistochemical PSMA heterogeneity, intensity and negative tumour area (PSMA&lt;sub>%neg&lt;/sub>) were correlated with spatially corresponding SUV&lt;sub>max&lt;/sub> on &lt;sup>68&lt;/sup>Ga-PSMA-11-PET in a multidisciplinary analysis.&lt;h4>Results&lt;/h4>All tumours showed medium to strong membranous (2-3 +) and weak to strong cytoplasmic (1-3 +) PSMA expression. Heterogeneously expressed PSMA was found in 38 cases (61%). Twenty-five cases (40%) showed at least 5% and up to 80% PSMA&lt;sub>%neg&lt;/sub>. PSMA&lt;sub>%neg&lt;/sub>, infiltrative growth pattern, smaller tumour area and diameter and WHO/ISUP grade group 2 significantly correlated with lower SUV&lt;sub>max&lt;/sub> values. A ROC curve analysis revealed 20% PSMA&lt;sub>%neg&lt;/sub> as an optimal cutoff with the highest sensitivity and specificity (89% and 86%, AUC 0.923) for a negative PSMA-PET scan. A multiple logistic regression model revealed tumoural PSMA&lt;sub>%neg&lt;/sub> (p &lt; 0.01, OR = 9.629) and growth pattern (p = 0.0497, OR = 306.537) as significant predictors for a negative PSMA-PET scan.&lt;h4>Conclusions&lt;/h4>We describe PSMA&lt;sub>%neg&lt;/sub>, infiltrative growth pattern, smaller tumour size and WHO/ISUP grade group 2 as parameters associated with a lower &lt;sup>68&lt;/sup>Ga-PSMA-11 uptake in prostate cancer. These findings can serve as fundament for future biopsy-based biomarker development to enable an individualized, tumour-adapted imaging approach.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2024-02-15T11:13:45.778Z</modification><creation>2022-02-11T11:43:26.686Z</creation></dates><accession>S-EPMC8484204</accession><cross_references><pubmed>34386839</pubmed><doi>10.1007/s00259-021-05501-1</doi></cross_references></HashMap>